SEARCH

SEARCH BY CITATION

References

  • Alexander S. P. H. and Millns P. J. (2001) [3H]ZM241385-an antagonist radioligand for adenosine A2A receptors in rat brain. Eur. J. Pharmacol. 411, 205210.
  • Angulo E., Casado V., Mallol J., Canela E. I., Vinals F., Ferrer I., Lluis C. and Franco R. (2003) A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 13, 440451.
  • Ascherio A. and Chen H. (2003) Caffeinated clues from epidemiology of Parkinson's disease. Neurology 61, S51S54.
  • Bal-Price A. and Brown G. C. (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21, 64806491.
  • Behan W. M. and Stone T. W. (2002) Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br. J. Pharmacol. 135, 14351442.
  • Brambilla R., Cottini L., Fumagalli M., Ceruti S. and Abbracchio M. P. (2003) Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43, 190194.
  • Brodie C., Blumberg P. M. and Jacobson K. A. (1998) Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett. 429, 139142.
  • Canals M., Angulo E., Casado V. et al. (2005) Molecular mechanisms involved in the adenosine A1 and A2a receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. J. Neurochem. 92, 337348.
  • Canas P., Rebola N., Rodrigues R. J., Oliveira C. R. and Cunha R. A. (2004) Increased adenosine A2A immunoreactivity in activated rat microglia in culture. FENS Abstr. 2, A223.9.
  • Chen J. F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., Moskowitz M. A., Fink J. S. and Schwarzschild M. A. (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19, 91929200.
  • Chen J. F., Xu K., Petzer J. P. et al. (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 21, RC143.
  • Coyle D. E. (1995) Adaptation of C6 glioma cells to serum-free conditions leads to the expression of a mixed astrocyte-oligodendrocyte phenotype and increased production of neurite-promoting activity. J. Neurosci. Res. 41, 374385.
  • Dehmer T., Lindenau J., Haid S., Dichgans J. and Schulz J. B. (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 22132216.
  • Ferré S., Karcz-Kubicha M., Hope B. T. et al. (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl Acad. Sci. USA 99, 1194011945.
  • Fiebich B. L., Biber K., Lieb K., Van Calker D., Berger M., Bauer J. and Gebicke-Haerter P. J. (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18, 152160.
  • Fiebich B. L., Butcher R. D. and Gebicke-Haerter P. J. (1998) Protein kinase C-mediated regulation of inducible nitric oxide synthase expression in cultured microglial cells. J. Neuroimmunol. 92, 170178.
  • Fink J. S., Kalda A., Ryu H., Stack E. C., Schwarzschild M. A., Chen J. F. and Ferrante R. J. (2004) Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88, 538544.
  • Gao Y. and Phillis J. W. (1994) CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55, L61L65.
  • Gebicke-Haerter P. J., Christoffel F., Timmer J., Northoff H., Berger M. and Van Calker D. (1996) Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem. Int. 29, 3742.
  • Giulian D. and Baker T. J. (1986) Characterization of ameboid microglia isolated from developing mammalian brain. J. Neurosci. 6, 21632178.
  • Golde S., Chandran S., Brown G. C. and Compston A. (2002) Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression. J. Neurochem. 82, 269282.
  • Haas H. L. and Selbach O. (2000) Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 362, 375381.
  • Heese K., Fiebich B. L., Bauer J. and Otten U. (1997) Nerve growth factor (NGF) expression in rat microglia is induced by adenosine A2a-receptors. Neurosci. Lett. 231, 8386.
  • Ikeda K., Kurokawa M., Aoyama S. and Kuwana Y. (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80, 262270.
  • Jones P. A., Smith R. A. and Stone T. W. (1998) Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res. 800, 328335.
  • Kim W. K., Jang P. G., Woo M. S., Han I. O., Piao H. Z., Lee K., Lee H., Joh T. H. and Kim H. S. (2004) A new anti-inflammatory agent KL-1037 represses pro-inflammatory cytokine and inducible nitric oxide synthase (iNOS) gene expression in activated microglia. Neuropharmacology 47, 243252.
  • Kim W. K., Kan Y., Ganea D., Hart R. P., Gozes I. and Jonakait G. M. (2000) Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-α production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J. Neurosci. 20, 36223630.
  • Klotz K. N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B. B. and Lohse M. J. (1998) Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. 357, 19.
  • Kust B. M., Biber K., Van Calker D. and Gebicke-Haerter P. J. (1999) Regulation of K+ channel mRNA expression by stimulation of adenosine A2a-receptors in cultured rat microglia. Glia 25, 120130.
  • Leibovich S. J., Chen J. F., Pinhal-Enfield G. et al. (2002) Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am. J. Pathol. 160, 22312244.
  • Li X. X., Nomura T., Aihara H. and Nishizaki T. (2001) Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci. 68, 13431350.
  • Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M. and Przedborski S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 14031409.
  • Maia L. and De Mendonca A. (2002) Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 9, 377382.
  • Milner R. and Campbell I. L. (2002) Cytokines regulate microglial adhesion to laminin and astrocyte extracellular matrix via protein kinase C-dependent activation of the α6β1 integrin. J. Neurosci. 22, 15621572.
  • Monopoli A., Lozza G., Forlani A., Mattavelli A. and Ongini E. (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9, 39553959.
  • Nakajima K., Kohsaka S., Tohyama Y. and Kurihara T. (2003) Activation of microglia with lipopolysaccharide leads to the prolonged decrease of conventional protein kinase C activity. Brain Res. Mol. Brain Res. 110, 9299.
  • Nakamura Y., Si Q. and Kataoka K. (2001) Differential regulation of microglial NO production by protein kinase C inhibitors. Neurochem. Int. 38, 17.
  • Nishizaki T., Nagai K., Nomura T. et al. (2002) A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia 39, 133147.
  • Peakman M. C. and Hill S. J. (1996) Adenosine A1 receptor-mediated inhibition of cyclic AMP accumulation in type-2 but not type-1 rat astrocytes. Eur. J. Pharmacol. 306, 281289.
  • Phillis J. W., Perkins L. M., Smith-Barbour M. and O'Regan M. H. (1995) Oxypurinol-enhanced post-ischemic recovery of the rat brain involves preservation of adenine nucleotides. J. Neurochem. 64, 21772184.
  • Pinhal-Enfield G., Ramanathan M., Hasko G., Vogel S. N., Salzman A. L., Boons G. J. and Leibovich S. J. (2003) An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am. J. Pathol. 163, 711721.
  • Popoli P., Pintor A., Domenici M. R. et al. (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 19671975.
  • Poucher S. M., Keddie J. R., Singh P., Stoggall S. M., Caulkett P. W., Jones G. and Coll M. G. (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br. J. Pharmacol. 115, 10961102.
  • Pyo H., Yang M. S., Jou I. and Joe E. H. (2003) Wortmannin enhances lipopolysaccharide-induced inducible nitric oxide synthase expression in microglia in the presence of astrocytes in rats. Neurosci. Lett. 346, 141144.
  • Rathbone M. P., Christjanson L., Deforge S., Deluca B., Gysbers J. W., Hindley S., Jovetich M., Middlemiss P. and Takhal S. (1992) Extracellular purine nucleosides stimulate cell division and morphogenesis: pathological and physiological implications. Med. Hypotheses 37, 232240.
  • Ross G. W., Abbott R. D., Petrovitch H., White L. R. and Tanner C. M. (2000) Relationship between caffeine intake and parkinson disease. J. Am. Med. Assoc. 284, 13781379.
  • Saura J., Tusell J. M. and Serratosa J. (2003) High-yield isolation of murine microglia by mild trypsinization. Glia 44, 183189.
  • Schubert P., Ogata T., Rudolphi K., Marchini C., McRae A. and Ferroni S. (1997) Support of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline. Ann. NY Acad. Sci. 826, 337347.
  • Schwarzschild M. A., Xu K., Oztas E., Petzer J. P., Castagnoli K., Castagnoli N. Jr and Chen J. F. (2003) Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 61, S55S61.
  • Si Q. S., Nakamura Y., Schubert P., Rudolphi K. and Kataoka K. (1996) Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp. Neurol. 137, 345349.
  • Sitkovsky M. V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., Ohta A. and Thiel M. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657682.
  • Solà C., Casal C., Tusell J. M. and Serratosa J. (2002) Astrocytes enhance lipopolysaccharide-induced nitric oxide production by microglial cells. Eur. J. Neurosci. 16, 12751283.
  • Stone T. W., Jones P. A. and Smith R. A. (2001) Neuroprotection by A2A receptor antagonists. Drug Dev. Res. 52, 323330.
  • Streit W. J. (2004) Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77, 18.
  • Sunohara J. R., Ridgway N. D., Cook H. W. and Byers D. M. (2001) Regulation of MARCKS and MARCKS-related protein expression in BV-2 microglial cells in response to lipopolysaccharide. J. Neurochem. 78, 664672.
  • Von Lubitz D. K., Lin R. C. and Jacobson K. A. (1995) Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur. J. Pharmacol. 287, 295302.
  • Wittendorp M. C., Boddeke H. W. and Biber K. (2004) Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia 46, 410418.
  • Yu L., Huang Z., Mariani J., Wang Y., Moskowitz M. and Chen J. F. (2004) Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med. 10, 10811087.